ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 251 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,964,302 | +89.4% | 142,241 | +117.6% | 0.11% | +86.4% |
| Q2 2023 | $1,565,396 | +8.6% | 65,361 | -14.7% | 0.06% | -1.7% |
| Q1 2023 | $1,441,800 | +374.7% | 76,610 | +301.5% | 0.06% | +233.3% |
| Q4 2022 | $303,754 | -47.4% | 19,080 | -45.9% | 0.02% | -50.0% |
| Q3 2022 | $577,000 | +25.2% | 35,255 | +7.9% | 0.04% | +111.8% |
| Q2 2022 | $461,000 | -18.8% | 32,687 | +34.4% | 0.02% | -34.6% |
| Q4 2021 | $568,000 | +111.2% | 24,319 | +120.5% | 0.03% | +52.9% |
| Q2 2021 | $269,000 | -74.5% | 11,030 | -73.0% | 0.02% | -67.3% |
| Q1 2021 | $1,055,000 | +133.4% | 40,875 | +383.7% | 0.05% | +160.0% |
| Q4 2020 | $452,000 | -78.2% | 8,450 | -83.2% | 0.02% | -79.4% |
| Q3 2020 | $2,072,000 | +158.4% | 50,240 | +203.5% | 0.10% | +136.6% |
| Q2 2020 | $802,000 | +3.4% | 16,552 | -8.8% | 0.04% | +20.6% |
| Q4 2019 | $776,000 | +28.7% | 18,151 | -19.5% | 0.03% | +3.0% |
| Q2 2019 | $603,000 | – | 22,550 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |